Humacyte rises on Symvess sale to military treatment facility
Source: SeekingAlpha
2025-07-23 14:30:48 ET
More on Humacyte
- Humacyte: Revenue Ramp From Symvess Incoming
- Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
- Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
- Humacyte jumps as DoD issues ECAT listing approval for Symvess
- Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026
Read the full article on Seeking Alpha
For further details see:
Humacyte rises on Symvess sale to military treatment facility
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
0.0% G/L:
$1.165 Last:
1,302,350 Volume:
$1.15 Open:
HUMA Latest News
February 18, 2026 08:00:00 am
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 09, 2026 08:00:00 am
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
